POTS is not officially classified as an autoimmune disease, but growing evidence suggests autoimmune mechanisms play a significant role in many cases. Postural orthostatic tachycardia syndrome is currently recognized as a multisystemic autonomic disorder affecting the neurological and cardiovascular systems. The relationship between POTS and autoimmunity is real and well-documented, though, and it’s reshaping how researchers and clinicians think about the condition.
How POTS Is Currently Classified
POTS is defined as a clinical syndrome, not a single disease with one cause. It’s diagnosed when standing triggers a sustained heart rate increase of at least 30 beats per minute in adults (40 in adolescents) within 10 minutes, without a corresponding drop in blood pressure. Symptoms include lightheadedness, palpitations, fatigue, blurred vision, exercise intolerance, and generalized weakness.
Because POTS can stem from several different underlying problems, including nerve damage, blood volume issues, and immune dysfunction, it doesn’t fit neatly into one category. Some patients have a primarily neuropathic form, others a hyperadrenergic form, and still others appear to have an autoimmune-driven form. This is part of why a blanket classification as “autoimmune” hasn’t happened: POTS is more of an umbrella that covers multiple mechanisms producing the same end result.
The Autoimmune Evidence
The strongest evidence linking POTS to autoimmunity comes from studies finding functional autoantibodies in patients’ blood. These are immune proteins that mistakenly target receptors in the body’s own nervous system, specifically the receptors that regulate heart rate and blood vessel constriction. In one study published in EP Europace, researchers tested 17 POTS patients and found that the majority carried autoantibodies targeting adrenergic receptors, the docking stations that adrenaline uses to control cardiovascular function. Activity levels of these autoantibodies were significantly higher in POTS patients compared to both healthy controls and people with simple fainting disorders.
What makes these autoantibodies particularly interesting is what they do. When researchers exposed cells to immune proteins (IgG) taken from POTS patients, two things happened simultaneously: the receptors responsible for constricting blood vessels became less responsive, and the receptors that speed up the heart became more responsive. That’s essentially the POTS pattern in a petri dish. Blood pools in the legs because vessels don’t tighten properly, and the heart races to compensate.
Beyond autoantibodies, POTS patients also show elevated levels of inflammatory signaling molecules. Studies have found significantly higher levels of several key immune markers, including TNF-alpha, interferon gamma, and certain interleukins, compared to normal values. This kind of chronic, low-grade immune activation is a hallmark of autoimmune conditions.
Why Viral Infections Often Trigger POTS
POTS frequently develops after a viral illness, a pattern that’s become even more visible since the COVID-19 pandemic. This post-infectious onset is one of the strongest clues pointing toward autoimmunity. The leading theory is molecular mimicry: a virus’s proteins resemble the body’s own receptor proteins closely enough that the immune system, while fighting the infection, accidentally learns to attack its own tissue. Once that misdirected immune response is established, it can persist long after the virus is gone.
Before COVID, infections like Epstein-Barr virus and influenza were the most commonly reported triggers. The pandemic dramatically increased the number of people developing POTS, and researchers have used this larger patient population to study the autoimmune connection more closely.
Overlap With Known Autoimmune Diseases
Between 16% and 20% of people with POTS also have a diagnosed autoimmune disease. In large surveys, the most common co-occurring autoimmune conditions include celiac disease (3%), Sjögren syndrome (3%), and systemic lupus erythematosus (2%). These numbers are higher than what you’d expect in the general population, which further supports an immune connection.
POTS also shares a striking demographic pattern with autoimmune diseases. It predominantly affects young women at a ratio of roughly 9 to 1 compared to men, and it most commonly appears during childbearing years. That female predominance mirrors conditions like lupus, Sjögren syndrome, and rheumatoid arthritis. POTS frequently clusters with other conditions that have suspected immune components, including hypermobility syndromes, chronic fatigue syndrome, migraines, and functional gut disorders.
What This Means for Treatment
Most POTS treatment still focuses on managing symptoms: increasing fluid and salt intake, wearing compression garments, graded exercise programs, and medications that help control heart rate or boost blood volume. These approaches help regardless of the underlying cause.
For patients whose POTS appears to be autoimmune-driven, though, immunotherapy is showing promise. Case reports have documented patients with confirmed autoantibodies responding to immunoglobulin therapy, which works by dampening the misdirected immune response. In one published case, a 35-year-old woman with autoimmune-mediated neuropathic POTS showed sustained clinical improvement with immunoglobulin treatment, and her improvement correlated directly with declining autoantibody levels over 22 months. These treatments are not yet standard of care and tend to be reserved for patients with clear evidence of immune dysfunction, but they represent a meaningful shift in how the condition is approached.
The practical takeaway is that if you have POTS, particularly if it developed after an infection or you have other autoimmune conditions, testing for autoantibodies may be worth discussing with your care team. Not every specialist offers this testing, and it isn’t part of the standard diagnostic workup yet, but identifying an autoimmune component can open up treatment options that go beyond symptom management.
The Bottom Line on Classification
POTS sits in a gray zone. It is not classified as an autoimmune disease, but a substantial subset of patients clearly have autoimmune mechanisms driving their symptoms. The evidence, from autoantibodies that directly replicate POTS physiology, to elevated inflammatory markers, to post-viral onset patterns, to overlap with established autoimmune diseases, is strong enough that many researchers now describe certain forms of POTS as autoimmune-mediated. The distinction matters because it’s not that POTS as a whole is autoimmune, but rather that autoimmunity is one of the most important and treatable causes of the syndrome.